Building the Future of Biodefense
Biothreat intelligence to deter and detect natural, accidental, deliberate and novel biological agents.
Biothreat intelligence to deter and detect natural, accidental, deliberate and novel biological agents.
Recommendation: Informational update only.
Situation: The WHO issued recommendations for the viral composition of influenza vaccines for the 2026-2027 northern hemisphere influenza season. The recommended strains for egg-based vaccines include an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1454/2025 (H3N2)-like virus, and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. The recommended strains for cell culture-, recombinant protein- or nucleic acid-based vaccines include an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1415/2025 (H3N2)-like virus, and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus. The announcement was made following a 4-day consultation examining global influenza surveillance data. Overall, influenza A viruses were predominant during the 2025-26 northern hemisphere respiratory season, with the A(H3N2) variant J.2.4.1 (“subclade K”) dominating following its emergence in August 2025 before spreading globally. Other variants of A(H3N2) and A(H1N1) were also recorded. Low levels of influenza B viruses (B/Victoria lineage) were detected, with no cases of B/Yamagata lineage viruses recorded since March 2020. [Confidence: Very High]
Recommendation: Spain has reported 4 human cases of swine influenza A(H1N1)v in the past 17 years, including a case in Catalonia reported in 2024. Limited, non-sustained human-to-human transmission of variant influenza viruses has previously been documented. Organizations can lower barriers to seasonal flu vaccines for their employees. Employees should avoid contact with diseased swine.
Situation: Spain confirmed a human case of influenza virus A(H1N1) variant of swine origin in Catalonia. The asymptomatic individual reported no history of exposure to pigs or a contaminated environment. Media sources reported that this infection may have resulted from human-to-human transmission, though other hypotheses are under investigation. Testing results from the case's direct contacts were all negative, suggesting that forward transmission has not occurred. Spain, European, and WHO officials stated that the risk level for the general public and for further transmission was Very Low. An investigation is ongoing. [Confidence: Very High]
Recommendation: Organizations in Suriname should reduce mosquito populations at their facilities by eliminating standing water. Employees can prevent mosquito bites by wearing protective clothing, using insect repellent, and eliminating standing water near their homes. Organizations should inform employees with planned work travel to affected countries and support pregnant employees who opt not to travel. Employees should consult a doctor about vaccination against chikungunya before traveling to affected areas. Vaccine eligibility and availability may vary by country.
Situation: Suriname health officials reported 1,150 chikungunya infections so far this year, with the virus spreading quickly and further across the country. By comparison, a 2014 outbreak saw 700 cases over 4 months, making the current outbreak far more rapid. Media sources reported that healthcare officials believe the actual number is likely much higher. Large-scale mosquito control efforts have not started yet due to insufficient pesticides and larvicides, though new shipments from Barbados and Brazil are expected. However, larvicides are still being used in some areas to fight mosquito larvae. Despite rising cases, hospitals remain able to manage patient care. Officials urged the public to help control the spread of the virus by removing stagnant water, wearing protective clothing, using repellents, and sleeping under mosquito nets. Earlier in the month, the US CDC issued a Level 2: Practice Enhanced Precautions travel advisory due to the chikungunya outbreak in Suriname (see PHC alert 2/6). See PHC alerts 2/11, 2/6, 1/30, and 1/22 for earlier info. [Confidence: Very High]
Recommendation: Informational update only.
Situation: A recent non-peer-reviewed study estimated the economic burden of measles in the US in 2025. The study found that measles cost more than $244 million in the US last year. Nearly two-thirds of the cost was due to outbreak response activities, while less than one-third of the costs were due to productivity loss. Direct medical expenses comprised 3% of costs. If measles vaccination coverage were to decline by 1% each year, annual costs could reach $1.5 billion in 2030. [Confidence: Very High]
Recommendation: Organizations in the United States should provide flexible work schedules to support employees making vaccine appointments for themselves or family members. Measles is highly contagious and can quickly spread among unvaccinated individuals in a work environment.
Situation: The US confirmed 1,130 measles cases across 28 states so far this year, excluding cases in international travelers to the US. Within the first 2 months of 2026, the country recorded just over half of all cases reported in all of 2025 (2,256). This week, additional cases were recorded in Pennsylvania and Minnesota, increasing the state totals to 12 and 10 cases, respectively (see PHC alert on 2/23). In Texas, 4 cases were confirmed in El Paso, as well as 13 additional cases at the East Montana federal ICE facility outside of the city, according to media sources. [Confidence: Very High]
Leverage operational biosurveillance to anticipate and assess biological risks, drive decision-making, and protect mission-critical operations.
PHC Navigator is a biothreat intelligence engine built on expert-curated and proprietary data and models that provides actionable intelligence and insights
© 2025 PHC Global. All rights reserved.
We are excited to show you the PHC Pharos Platform in action!
Enter your contact information and we'll reach out to schedule a demo.